Loading
Strata Oncology's tumour gene test built for very small biopsies, which also gives a score predicting benefit from PD-1 and PD-L1 immunotherapy.
Strata Oncology's tissue test was described in 2021 as StrataNGS, a 429-gene laboratory-developed test performed on DNA and RNA from tumour specimens with at least 2 mm² of tumour, validated on 1,986 clinical samples to MolDX guidelines. By 2023 Strata presented it as Strata Select: DNA and quantitative RNA sequencing across 437 genes from a single small sample, with tumour mutational burden, microsatellite instability, an Immunotherapy Response Score, RNA-based results for antibody-drug conjugate targets and homologous recombination deficiency for ovarian cancer, and the old StrataNGS address now redirects to the Strata Select one. The Immunotherapy Response Score combines tumour mutational burden with expression of CD274 (PD-L1), PDCD1 (PD-1), ADAM12 and TOP2A, and was developed and validated in patients treated with PD-1 or PD-L1 inhibitors. Strata's 2023 page stated that Strata Select is covered by Medicare Part B and Medicare Advantage.
Multiplex PCR and semiconductor sequencing of DNA and RNA co-isolated from formalin-fixed tumour tissue, designed to work on samples with as little as 2 mm² of tumour.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Strata Select" OR ABSTRACT:"Strata Select" OR TITLE:"StrataNGS" OR ABSTRACT:"StrataNGS" OR TITLE:"Strata Oncology StrataNGS" OR ABSTRACT:"Strata Oncology StrataNGS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Strata Select, not a curated reading list.
Shares Immunotherapy response and its prediction, TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares MSI-high (microsatellite instability by PCR or sequencing), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Metastatic cancer (cancer that has spread) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/